Crosstalk of Autophagy and Apoptosis

Maurizio Sorice

Department of Experimental Medicine, “Sapienza” University of Rome, 00161 Rome, Italy; maurizio.sorice@uniroma1.it; Tel.: +39-6-49972675

Abstract: Autophagy and apoptosis represent two fundamental pathophysiological mechanisms of cell fate regulation. However, the signaling pathways of these processes are significantly interconnected through various mechanisms of crosstalk. Indeed, autophagy/apoptosis crosstalk is still an emerging field, in which an increasing number of molecules are involved, including, for example, PINK1 and ERLINs. On the other hand, this crosstalk involves signal transduction pathways which are strongly dependent on Ca$^{2+}$. Interestingly, crosstalk between autophagy and apoptosis impacts several pathologies, including multiple rheumatic diseases. The purpose of this Special Issue is also to investigate the bioactive properties of drugs with antitumor activity, focusing particularly on the role of anthraquinone derivatives in the regulation of cell death and autophagy crosstalk. This Special Issue of Cells brings together the most recent advances in understanding the various aspects of crosstalk between autophagy and apoptosis and the interconnected signaling pathways, implying therapeutic perspectives for the utility of its modulation in an anti-cancer setting.

Keywords: autophagy; apoptosis; cell signaling; lipid rafts; calcium; PINK1; cancer therapy
regulating cell homeostasis [3]. In this way, specific plasma membrane microdomains, named lipid rafts, regulate a variety of signal transduction pathways involved in specific cellular programs, including proliferation, apoptosis, differentiation, stress responses and autophagy, thus determining cell fate [4]. However, lipid rafts are not only in the plasma membrane [5], but are also present in the membrane of intracellular organelles, including ER, Golgi apparatus, endosomes, lysosomes. At these sites, key reactions can be catalyzed with a significant impact on the regulation of intracellular trafficking and sorting, cholesterol homeostasis and cell fate. Mitochondria-associated membranes (MAMs) have been classified as critical “hubs” in the regulation of apoptosis, autophagy and tumor growth. Recently, the discovery of lipid rafts as physical and functional platforms within MAMs, contributed to the elucidation of mechanisms underlying the early steps of the autophagic process [6]. In particular, it is emerging that ER lipid raft-like microdomain proteins, i.e., ER lipid raft-associated protein 1 (ERLIN1) and 2 (ERLIN2), may drive mitochondria-ER crosstalk under both physiological and pathological conditions by association with MAMs, thus regulating survival and death. Manganelli et al. describe the role of ERLINs in determining cell fate by controlling the “interchange” between apoptosis and autophagy pathways [7]. The proposed role of ERLINs in the degradation of the calcium channel (inositol 1,4,5-triphosphate receptor), could explain their role in the autophagy mechanism, adding a significant impact on the pathogenesis of several human diseases.

Indeed, crosstalk between autophagy and apoptosis impacts several pathologies, including multiple rheumatic diseases. Since mitochondria are significant regulators in maintaining cartilage homeostasis, turnover of mitochondria through mitochondrial biogenesis and mitochondrial degradation may play an important role in the pathogenesis of osteoarthritis (OA). Kim et al. discuss the role of mitochondrial dysfunction in OA pathogenesis, identifying the peroxisome proliferator-activated receptor-gamma co-activator 1-alpha (PGC1α) as a potent regulator [8]. They demonstrated that the loss of PGC1α in chondrocytes due to upregulation of miR-126-5p during OA pathogenesis culminated in the activation of PRKN-independent mitophagy through BNIP3 upregulation and stimulated cartilage degradation and apoptotic death of chondrocytes. In addition, the dysregulated balance between autophagy and apoptosis may be involved in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus and Sjogren’s syndrome [9]. Indeed, it may regulate the survival of immune cells, peptide citrullination, the presentation of autoantigens, and B- and T-cell maturation. Notably, some currently used disease-modifying antirheumatic drugs (DMARDs), including glucocorticoids, hydroxychloroquine, rapamycin, anti-TNFα and Jak inhibitors may act through autophagy/apoptosis pathways.

The purpose of this Special Issue is also to investigate the bioactive properties of drugs with antitumor activities, focusing on their role in the regulation of autophagy and cell death crosstalk that triggers the uncontrolled expansion of tumor cells. In this vein, an example is represented by anthraquinone derivatives, which may affect autophagy and/or apoptosis and promote oxidative changes in cancer cells [10,11]. In particular, Trybus et al. [10] showed that physcion induces an increased number of lysosomes, autophagy vacuoles, and upregulation of the LC3 protein level. At the same time, the pro-apoptotic effect of physcion was identified and this mechanism was dependent on caspases 3/7 activation together with a reduction in Bcl-2 expression. The induction of apoptosis and autophagy may represent a common mechanism for the anti-tumor effect of physcion. Morgan et al. analyzed the effects of a wider panel of anthraquinone derivatives tested in the colon, prostate, liver and cervical cancer cell lines [11]. Among these compounds, 1,4-bis(benzyloxy)-2,3-bis(hydroxymethyl)anthracene-9,10-dione was shown to induce apoptosis through the activation of caspases and the production of PARP. Moreover, autophagy also plays a role in its mechanism of action since it activates the conversion of LC3A/B-I to LC3A/B-II and causes p70 s6 kinase phosphorylation.

Altogether, the articles in this Special Issue further improve the knowledge of the mechanisms regulating cell fate, analyzing either the signaling pathways regulating cell death and survival or the bioactive properties of drugs acting on the crosstalk between
autophagy and apoptosis. This understanding may drive the development of a new therapeutic strategy for cancer and/or autoimmune diseases.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Brunelli, F.; Torosantucci, L.; Gelmetti, V.; Franzone, D.; Grünewald, A.; Krüger, R.; Arena, G.; Valente, E.M. PINK1 Protects against Staurosporine-Induced Apoptosis by Interacting with Beclin1 and Impairing Its Pro-Apoptotic Cleavage. *Cells* **2022**, *11*, 678. [CrossRef] [PubMed]

2. Sukumaran, P.; Da Conceicao, V.N.; Sun, Y.; Ahamad, N.; Saraiva, L.R.; Selvaraj, S.; Singh, B.B. Calcium Signaling Regulates Autophagy and Apoptosis. *Cells* **2021**, *10*, 2125. [CrossRef] [PubMed]

3. Sezgin, E.; Levental, I.; Mayor, S.; Eggeling, C. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 361–374. [CrossRef] [PubMed]

4. Sezgin, E.; Gutmann, T.; Buhl, T.; Dirks, R.; Grzybek, M.; Coskun, Ü.; Solimena, M.; Simons, K.; Levental, I.; Schwille, P. Adaptive Lipid Packing and Bioactivity in Membrane Domains. *PLoS ONE* **2015**, *10*, e0123930. [CrossRef] [PubMed]

5. Garofalo, T.; Manganelli, V.; Grasso, M.; Mattei, V.; Ferri, A.; Misasi, R.; Sorice, M. Role of mitochondrial raft-like microdomains in the regulation of cell apoptosis. *Apoptosis* **2015**, *20*, 621–634. [CrossRef] [PubMed]

6. Manganelli, V.; Longo, A.; Mattei, V.; Recalchi, S.; Riitano, G.; et al. Raft-like lipid microdomains drive autophagy initiation via AMBRA1-ERLIN1 molecular association within MAMs. *Autophagy* **2021**, *17*, 2528–2548. [CrossRef] [PubMed]

7. Manganelli, V.; Longo, A.; Mattei, V.; Recalchi, S.; Riitano, G.; Caissutti, D.; Capozzi, A.; Sorice, M.; Misasi, R.; Garofalo, T. Role of ERLINs in the Control of Cell Fate through Lipid Rafts. *Cells* **2021**, *10*, 2408. [CrossRef] [PubMed]

8. Kim, D.; Song, J.; Jin, E. BNIP3-Dependent Mitophagy via PGC1α Promotes Cartilage Degradation. *Cells* **2021**, *10*, 1839. [CrossRef] [PubMed]

9. Celia, A.I.; Colafrancesco, S.; Barbati, C.; Alessandri, C.; Conti, F. Autophagy in Rheumatic Diseases: Role in the Pathogenesis and Therapeutic Approaches. *Cells* **2022**, *11*, 1359. [CrossRef] [PubMed]

10. Trybus, W.; Król, T.; Trybus, E.; Stachurska, A. Physcion Induces Potential Anticancer Effects in Cervical Cancer Cells. *Cells* **2021**, *10*, 2029. [CrossRef] [PubMed]

11. Morgan, I.; Wessjohann, L.A.; Kaluderović, G.N. In Vitro Anticancer Screening and Preliminary Mechanistic Study of A-Ring Substituted Anthraquinone Derivatives. *Cells* **2022**, *11*, 168. [CrossRef] [PubMed]